F
Franz Fazekas
Researcher at Medical University of Graz
Publications - 634
Citations - 59050
Franz Fazekas is an academic researcher from Medical University of Graz. The author has contributed to research in topics: Hyperintensity & Stroke. The author has an hindex of 101, co-authored 629 publications receiving 49775 citations. Previous affiliations of Franz Fazekas include Hospital of the University of Pennsylvania & University of Graz.
Papers
More filters
Journal ArticleDOI
Lipocalin-2 as an Infection-Related Biomarker to Predict Clinical Outcome in Ischemic Stroke
Sonja Hochmeister,Odilo Engel,Milena Z. Adzemovic,Thomas Pekar,Thomas Pekar,Paul Kendlbacher,Paul Kendlbacher,Manuel Zeitelhofer,Michaela Tanja Haindl,Andreas Meisel,Franz Fazekas,Thomas Seifert-Held +11 more
TL;DR: Plasma levels of LCN2 measured in patients one week after ischemic stroke contribute to the prediction of clinical outcome at 90 days and reflect the systemic response to post-stroke infections.
Journal ArticleDOI
Rheological aspects of cerebrovascular disease.
TL;DR: Abnormal rheologic conditions can be measured as increased blood viscosity and may be caused by corpuscular as well as by plasmatic factors.
Journal ArticleDOI
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
Franz Fazekas,Ovidiu Bajenaru,Thomas Berger,Tanja Hojs Fabjan,Alenka Horvat Ledinek,Gábor Jakab,Sámuel Komoly,Tetiana Kobys,Jörg Kraus,Egon Kurča,Theodoros Kyriakides,L'ubomír Lisý,Ivan Milanov,Tetyana Nehrych,Sergii Moskovko,Panayiotis Panayiotou,Saša Šega Jazbec,Larysa Sokolova,Radomír Taláb,Latchezar Traykov,Peter Turcani,Karl Vass,Norbert Vella,Nataliya Voloshyná,Eva Havrdova +24 more
TL;DR: Fingolimod (Gilenya®) is the first oral treatment of MS and has recently been approved as single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis (RRMS) for adult patients with high disease activity despite basic treatment and for treatment-naïve patients with rapidly evolving severe RRMS.
Journal ArticleDOI
Prevalence and short‐term changes of cognitive dysfunction in young ischaemic stroke patients
Daniela Pinter,Christian Enzinger,Thomas Gattringer,Sebastian Eppinger,Kurt Niederkorn,Susanna Horner,Simon Fandler,Markus Kneihsl,K. Krenn,Gerhard Bachmaier,Franz Fazekas +10 more
TL;DR: Assessment of a consecutive sample of acute young ischaemic stroke patients (18–55 years) for the presence and development of neuropsychological deficits found the presence of post‐stroke cognitive impairment.
Journal ArticleDOI
Management of right-to-left shunt in cryptogenic cerebrovascular disease: results from the observational Austrian paradoxical cerebral embolism trial (TACET) registry
Susanna Horner,Kurt Niederkorn,Thomas Gattringer,Martin Furtner,Raffi Topakian,Wilfried Lang,Robert Maier,Andreas Gamillscheg,Franz Fazekas +8 more
TL;DR: The possible causes for paradoxical embolism in young patients with cryptogenic stroke appear more variable than usually considered, and other causes than PFO should not be neglected.